Biotech companies struggle to secure clinical trial financing for promising cell therapy programs

Biotech firms developing innovative cancer treatments face critical funding gaps that force them to abandon clinical trials and shelve years of R&D investment. Companies like Caribou Biosciences lack access to reliable financing mechanisms for mid-stage clinical development, causing promising therapies to die in development despite scientific merit. Current venture capital and traditional biotech funding channels are insufficient and unpredictable for sustaining multi-year clinical programs.